Lilly’s diabetes med Trulicity shrugs off Novo Nordisk challenge

Lilly’s diabetes med Trulicity shrugs off Novo Nordisk challenge

Source: 
Pharmaforum
snippet: 

Eli Lilly’s crop of new products propelled the company to 8% sales growth in the fourth quarter, but the most pleasing aspect for the firm was likely the resilience of its diabetes blockbuster Trulicity.